apixaban,enoxaparin
bms,pfizer
['vte', 'eliquis', 'freedom covid']
major trials from acc this year:
1.freedom covid: sample size: 3,398. results: prophylactic vs therapeutic lovenox/eliquis in non critical covid-19 patients does not reduce mortality, vte or stroke. 13.2% vs 11.3% rate of incidence of thromboembolic events. #continued #acc2023
Cardiology Fellow Class of 2024. Micropuncture specialist! Medicine, Hiking. Sleep, Study & Repeat. 🇵🇰 🇺🇸 Tweets are definitely mine.